ストックスクリーナーアプリを入手
1.33
0.00%
0.00
アフターアワーズ：
1.34
0.01
+0.75%
前日終値:
$1.33
開ける：
$1.36
24時間の取引高:
3.74M
Relative Volume:
0.84
時価総額：
$435.34M
収益：
-
当期純損益:
$-63.08M
株価収益率:
-4.9259
EPS:
-0.27
ネットキャッシュフロー:
$-72.53M
1週間 パフォーマンス:
-8.28%
1か月 パフォーマンス:
-13.64%
6か月 パフォーマンス:
+38.79%
1年 パフォーマンス:
+83.52%
1日の値動き範囲:
$1.32
$1.3895
1週間の範囲:
$1.31
$1.52
52週間の値動き範囲:
$0.515
$1.96
Ocugen Inc Stock (OCGN) Company Profile
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.33 | 435.34M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen grants CEO new performance-based equity award - MSN
Wall Street Recap: Can Ocugen Inc be recession proof2025 Price Action Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Breakout Move: Will Ocugen Inc stock recover after earningsJuly 2025 Levels & Real-Time Market Trend Scan - baoquankhu1.vn
Ocugen’s Gene Therapy Progress and Funding Extend Runway - AD HOC NEWS
Ocugen Shares Stabilize Following Recent Equity Offering - AD HOC NEWS
Trade Report: Can Ocugen Inc be recession proofWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MSN
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
What are analysts price targets for Ocugen IncJuly 2025 Volume & Long Hold Capital Preservation Tips - baoquankhu1.vn
Valuation Update: Can Belite Bio Inc Depositary Receipt deliver alphaWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
RSI Check: Can Ocugen Inc weather a recessionWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Ocugen’s Gene Therapy Candidate Shows Promise in Early-Stight Loss Trial - AD HOC NEWS
Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial - NeurologyLive
Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial - CGTLive®
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 - MyChesCo
Macro Review: Is Ocugen Inc forming a double bottom2025 Volatility Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ocugen Stock: A Turnaround Fueled by Promising Trial Data - AD HOC NEWS
Ocugen’s Clinical Pipeline Takes Center Stage Following Capital Raise - AD HOC NEWS
How The Narrative Around Ocugen (OCGN) Is Shifting After The Latest Price Target Change - Yahoo Finance
Ocugen Secures Financial Runway Through Strategic Capital Raise - AD HOC NEWS
Ocugen Secures Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Ocugen Secures Funding at a Short-Term Cost to Shareholders - AD HOC NEWS
Ocugen Shares Defy Dilution Fears on Strong Clinical Data - AD HOC NEWS
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - Sahm
Ocugen closes $22.5 million registered direct offering By Investing.com - Investing.com South Africa
Ocugen Secures Financial Runway Through 2026 - AD HOC NEWS
How Fresh Capital And Positive OCU410 Data At Ocugen (OCGN) Has Changed Its Investment Story - Yahoo Finance
Ocugen strengthens balance sheet with new equity financing - TipRanks
Ocugen, Inc. Closes $22.5 Million Stock Offering - TradingView
Ocugen closes $22.5 million registered direct offering - Investing.com
Ocugen (NASDAQ: OCGN) reports strong midstage data for gene therapy - MSN
Ocugen Announces $22.5 Million Public Stock Offering - The Globe and Mail
Ocugen (NASDAQ:OCGN) Trading 12.4% HigherTime to Buy? - MarketBeat
Ocugen Stock Faces Dilution After Capital Raise - AD HOC NEWS
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy - MyChesCo
Ocugen prices $22.5 million common stock offering at $1.50 per share - Investing.com Nigeria
Ocugen prices $22.5 million common stock offering at $1.50 per share By Investing.com - Investing.com South Africa
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen Signs Underwriting Agreement With Oppenheimer & Co - TradingView
Form 424B5 Ocugen, Inc. - StreetInsider
Ocugen shares slide after company prices $22.5 million equity raise - MSN
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - Ocugen, Inc.
Ocugen (OCGN) Prices $22.5 Million Stock Offering - GuruFocus
Ocugen drops on stock offering - TradingView
Ocugen (OCGN) Prices Stock Offering to Raise $22.5 Million - GuruFocus
Ocugen stock falls after pricing $22.5 million common share offering By Investing.com - Investing.com Nigeria
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
1.25%
大文字化:
|
ボリューム (24 時間):